Proteus is focused exclusively on transforming healthcare through regenerative medicine. Our objective is to provide the capital, scientific insight, and business leadership to launch and support the most successful regenerative medicine companies in the world.
The Fund will invest in 5 areas:
|
Cell Therapies: Therapies that utilize cells or compounds designed to repair or regenerate a patients damaged, aging or diseased organs. Near term applications include heart disease, diabetes, vision impairments, and Parkinson’s disease. Tissue Engineering: Therapies that employ a scaffold or delivery system to create functional tissues and organs. Near term applications include bone regrowth, intervertebral disk repair, and urinary bladder or corneal replacements. |
Tools & Devices: Companies creating cell lines that embody genetic defects or disease characteristics that are used for the discovery, screening and development of new drugs. This sector also includes companies developing devices that are designed to enable regenerative medicine related procedures, such as specialized devices for the harvest, processing, selection and delivery of stem cells, cell-based diagnostic tools, etc. Regenerative Compounds: Compounds that trigger endogenous regeneration. This sector includes new chemical entities, growth factors, proteins, and other compounds that trigger cell and tissue regrowth, as well as advanced wound and fracture repair. Aesthetic Medicine: Companies developing cell therapies, tissues and biomaterials for cosmetic applications. This sector comprises hair follicle cells for hair regeneration, and collagen-secreting human dermal fibroblasts for facial wrinkles and other skin disorders. |